IRAK inhibitor 4 - CAS 1012104-68-5
Catalog number:
1012104-68-5
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C33H35F3N6O3
Molecular Weight:
620.66
COA:
Inquire
Targets:
IRAK
Description:
IRAK inhibitor 4 is interleukin-1 receptor associated kinase inhibitor.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
MSDS:
Inquire
1.Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats.
Kondo M1, Tahara A, Hayashi K, Abe M, Inami H, Ishikawa T, Ito H, Tomura Y. Naunyn Schmiedebergs Arch Pharmacol. 2014 Oct;387(10):909-19. doi: 10.1007/s00210-014-1023-z. Epub 2014 Jul 23.
Renal inflammation is a final common pathway of chronic kidney disease (CKD), and its progression can be used to effectively gauge the degree of renal dysfunction. Interleukin-1 (IL-1) receptor-associated kinase 4 (IRAK-4) has been reported to be a pivotal molecule for IL-1 receptor- and Toll-like receptor-induced signaling and activation of proinflammatory mediators. In this study, we hypothesized that if inflammation plays a key role in renal failure, then the anti-inflammatory effect of IRAK-4 inhibitor should be effective in improving CKD. To determine its pharmacological potency, we investigated the renoprotective properties of the novel IRAK-4 inhibitor AS2444697 (N-[3-carbamoyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide hydrochloride (1:1)) in 5/6 nephrectomized (Nx) rats, a model of CKD. Six weeks' repeated administration of AS2444697 (0.3-3 mg/kg, twice daily) dose-dependently and significantly reduced urinary protein excretion and prevented the development of glomerulosclerosis and interstitial fibrosis without affecting the blood pressure.
2.The structure function of the death domain of human IRAK-M.
Du J, Nicolaes GA, Kruijswijk D, Versloot M, van der Poll T, van 't Veer C. Cell Commun Signal. 2014 Dec 7;12:77. doi: 10.1186/s12964-014-0077-3.
BACKGROUND: IRAK-M is an inhibitor of Toll-like receptor signaling that acts by re-directing IRAK-4 activity to TAK1 independent NF-κB activation and by inhibition of IRAK-1/IRAK-2 activity. IRAK-M is expressed in monocytes/macrophages and lung epithelial cells. Lack of IRAK-M in mice greatly improves the resistance to nosocomial pneumonia and lung tumors, which entices IRAK-M as a potential therapeutic target. IRAK-M consists of an N-terminal death domain (DD), a dysfunctional kinase domain and unstructured C-terminal domain. Little is known however on IRAK-M's structure-function relationships.
3.The IRAK-ERK-p67phox-Nox-2 axis mediates TLR4, 2-induced ROS production for IL-1β transcription and processing in monocytes.
Singh A1, Singh V1, Tiwari RL1, Chandra T2, Kumar A3, Dikshit M1, Barthwal MK1. Cell Mol Immunol. 2015 Aug 31. doi: 10.1038/cmi.2015.62. [Epub ahead of print]
In monocytic cells, Toll-like receptor 4 (TLR4)- and TLR2-induced reactive oxygen species (ROS) cause oxidative stress and inflammatory response; however, the mechanism is not well understood. The present study investigated the role of interleukin-1 receptor-associated kinase (IRAK), extracellular signal-regulated kinase (ERK), p67phox and Nox-2 in TLR4- and TLR2-induced ROS generation during interleukin-1 beta (IL-1β) transcription, processing, and secretion. An IRAK1/4 inhibitor, U0126, PD98059, an NADPH oxidase inhibitor (diphenyleneiodonium (DPI)), and a free radical scavenger (N-acetyl cysteine (NAC))-attenuated TLR4 (lipopolysaccharide (LPS))- and TLR2 (Pam3csk4)-induced ROS generation and IL-1β production in THP-1 and primary human monocytes. An IRAK1/4 inhibitor and siRNA-attenuated LPS- and Pam3csk4-induced ERK-IRAK1 association and ERK phosphorylation and activity. LPS and Pam3csk4 also induced IRAK1/4-, ERK- and ROS-dependent activation of activator protein-1 (AP-1), IL-1β transcription, and IL-1β processing because significant inhibition in AP-1 activity, IL-1β transcription, Pro- and mature IL-β expression, and caspase-1 activity was observed with PD98059, U0126, DPI, NAC, an IRAK1/4 inhibitor, tanshinone IIa, and IRAK1 siRNA treatment.
4.IRAK-M promotes alternative macrophage activation and fibroproliferation in bleomycin-induced lung injury.
Ballinger MN1, Newstead MW2, Zeng X2, Bhan U2, Mo XM3, Kunkel SL4, Moore BB2, Flavell R5, Christman JW6, Standiford TJ2. J Immunol. 2015 Feb 15;194(4):1894-904. doi: 10.4049/jimmunol.1402377. Epub 2015 Jan 16.
Idiopathic pulmonary fibrosis is a devastating lung disease characterized by inflammation and the development of excessive extracellular matrix deposition. Currently, there are only limited therapeutic intervenes to offer patients diagnosed with pulmonary fibrosis. Although previous studies focused on structural cells in promoting fibrosis, our study assessed the contribution of macrophages. Recently, TLR signaling has been identified as a regulator of pulmonary fibrosis. IL-1R-associated kinase-M (IRAK-M), a MyD88-dependent inhibitor of TLR signaling, suppresses deleterious inflammation, but may paradoxically promote fibrogenesis. Mice deficient in IRAK-M (IRAK-M(-/-)) were protected against bleomycin-induced fibrosis and displayed diminished collagen deposition in association with reduced production of IL-13 compared with wild-type (WT) control mice. Bone marrow chimera experiments indicated that IRAK-M expression by bone marrow-derived cells, rather than structural cells, promoted fibrosis.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related IRAK Products


PF-06650833
(CAS: 1817626-54-2)

PF-06650833, is an inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4) which is an omnipresently expressed serine/threonine kinase involved in the r...

CAS 1042672-97-8 IRAK inhibitor 6

IRAK inhibitor 6
(CAS: 1042672-97-8)

IRAK inhibitor 6 is interleukin-1 receptor associated kinase 4 (IRAK-4) inhibitor .

CAS 509093-47-4 IRAK-1-4 Inhibitor I

IRAK-1-4 Inhibitor I
(CAS: 509093-47-4)

IRAK-1-4 Inhibitor I is a novel benzimidazole that is a potent inhibitor of interleukin-1 receptor-associated kinases 1-4 (IRAK 1-4).

AZ-1495

AZ-1495 is a novel inhibitor of interleukin-1 receptor-associated kinases (IRAKs), a component in the signal transduction pathways utilized by IL-1R, IL-18R and...

CAS 1042224-63-4 IRAK inhibitor 1

IRAK inhibitor 1
(CAS: 1042224-63-4)

IRAK inhibitor 1 is interleukin-1 receptor associated kinase 4 (IRAK-4) inhibitor.

CAS 1012343-93-9 IRAK inhibitor 3

IRAK inhibitor 3
(CAS: 1012343-93-9)

IRAK inhibitor 3 is interleukin-1 receptor associated kinase inhibitor.

CAS 928333-30-6 IRAK inhibitor 2

IRAK inhibitor 2
(CAS: 928333-30-6)

IRAK inhibitor 2 is interleukin-1 receptor associated kinase inhibitor .

R-191

R-191 is an IRAK-4 inhibitor that has the potential to treat hematological malignancy. Studies showed that it inhibited the production of cytokines induced by T...

CAS 1012104-68-5 IRAK inhibitor 4

IRAK inhibitor 4
(CAS: 1012104-68-5)

IRAK inhibitor 4 is interleukin-1 receptor associated kinase inhibitor.

JH-X-119-01 hydrochloride

A potent IRAK1 inhibitor

CAS 1287665-60-4 AS-2444697 HCl

AS-2444697 HCl
(CAS: 1287665-60-4)

AS-2444697 is a pootent and selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor (IC50 = 21 nM) with 30-fold selectivity for IRAK4 over IRAK1....

Chemical Structure

CAS 1012104-68-5 IRAK inhibitor 4

Quick Inquiry

Verification code

Featured Items